Blog

 

 

 

Quality

Everyone deserves a fair and just opportunity to attain their optimal health and well-being.  For far too long, this ideal has felt out of reach for many individuals living with Sickle Cell Disease (SCD). Sickle Cell Disease – an inherited blood disorder, affects approximately 100,000 individuals in the United States, the majority of whom are Black/African American, and/or Hispanic.

Improving the organ transplantation system is a priority for the Biden-Harris Administration.  In 2021, the Department of Health and Human Services Secretary Becerra established a coordinated effort to improve organ donation, procurement, and transplantation.  Led by the Centers for Medicare & Medicaid Services (CMS) and the Health Resources and Services Administration (HRSA), this collaborative seeks to drive improvements in donations, clinical outcomes, system improvement, quality measurement, transparency, and regulatory oversight. 

The Centers for Medicare & Medicaid Services (CMS) and the Health Resources and Services Administration (HRSA) are federal agencies within the U.S. Department of Health and Human Services (HHS) that play important roles in protecting the health and safety of Americans as they engage with the U.S. healthcare system. The agencies share responsibility for overseeing the organ donation, procurement, and transplantation system.

A True Focus on Data to Advance Health Equity

The Centers for Medicare & Medicaid Services (CMS) administers health care coverage for more than 150 million individuals through Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and the Marketplace – HealthCare.gov. The vision of the agency is straightforward: To serve the public as a trusted partner and steward, dedicated to advancing health equity, expanding access to affordable coverage and care, and improving health outcomes – the latter being key to this discussion.

The Centers for Medicare & Medicaid Services (CMS) is committed to ensuring people on Medicare have quicker access to innovative medical technologies for life-threatening or irreversibly debilitating diseases – like cancer and heart disease.